# A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

> **NCT00431236** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 810 (actual)

## Conditions studied

- Nausea and Vomiting, Chemotherapy-Induced

## Interventions

- **DRUG:** Oral Casopitant (GW679769)
- **DRUG:** IV Casopitant (GW679769)
- **DRUG:** IV ondansetron hydrochloride
- **DRUG:** Oral dexamethasone

## Key facts

- **NCT ID:** NCT00431236
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-06
- **Primary completion:** 2007-10-09
- **Final completion:** 2007-10-09
- **Target enrollment:** 810 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431236, "A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00431236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*